A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection

Clinical trial NCT05070546 · COMPLETED

Trial details

NCT number: NCT05070546
Sponsor: Janssen Vaccines & Prevention B.V.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Respiratory Syncytial Virus Infection Prevention

Start date: 2021-09-29
Primary completion: 2022-08-12
Enrollment: 1124

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.